News
Current position:Product Center > Cell lines > Cytokines > TGF-β > TGF-β Reporter HEK-293 cell line
TGF-β Reporter HEK-293 cell line
Description
Cat. No: GM-C05346
Product: TGF-β Reporter HEK-293 Cell Line


TGF-Beta (Transforming Growth Factor-Beta) is a type of multifunctional cytokine and a member of the cytokine superfamily. It plays a vital role in various biological processes such as cell growth, differentiation, apoptosis, and immune regulation. The TGF-Beta family includes three homologous isoforms: TGF-β1, TGF-β2, and TGF-β3. While structurally similar, they function differently across various tissues and cell types.

TGF-Beta works by binding to TGF-Beta receptors on cell surfaces, activating downstream signaling pathways. The main pathways include the Smad-dependent and non-Smad pathways. Smad proteins play a critical role in TGF-Beta signal transduction, relocating to the cell nucleus once receptors are activated to regulate the expression of specific genes.

TGF-β Reporter HEK-293 Cell Line is a clonal stable HEK-293 cell line with constitutive expression of the TβRI, endogenously expresses TβRII gene and some adapter membrane molecules, along with signal-dependent expression of a luciferase reporter gene. When TGF-β binds to TGF-β receptors, it activates  downstream signaling pathways, leading to the expression of luciferase. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to this signaling pathway.
Data
Response to Recombinant Human TGF-beta 1. TGF-β Reporter HEK-293 Cell Line (Cat. GM-C05346) at a concentration of 2.5E4 cells/well (96-well format) was stimulated with serial dilutions of Recombinant Human TGF-beta 1 (novoprotein/CA59) in assay buffer (DMEM +10% FBS +1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Assay System (Cat. GM-040501). The maximum induction fold was approximately [8.0]. Data are shown by drug mass concentration.
Specifications
Cat. NoGM-C05346
ProductTGF-β Reporter HEK-293 Cell Line
Product Format1 vial of frozen cells
Quantity5E6 Cells per vial,1 mL
Storage ConditionsLiquid nitrogen immediately upon receipt
Recovery MediumDMEM+10% FBS+1% P.S
Growth mediumDMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+125 μg/mL Hygromycin+0.75 μg/mL Puromycin
NoteNone
Freezing Medium90% FBS+10% DMSO
Growth propertiesAdherent
Growth Conditions37°C, 5% CO₂
Safety considerationsBiosafety Level 2
Mycoplasma TestingThe cell line has been screened to confirm the absence of Mycoplasma species.
Materials
ReagentOrdering Information
DMEM, high glucose, with glutamineBiological Industries/01-052-1ACS
Fetal Bovine SerumCegrogen biotech/A0500-3010
Pen/StrepThermo/15140-122
BlasticidinGenomeditech/GM-040404
G418Genomeditech/GM-040402
HygromycinGenomeditech/GM-040403
PuromycinGenomeditech/GM-040401
Recombinant Human TGF-beta 1Novoprotein/CA59
Luciferase Reporter Gene Aassy Kit(the Kit is replaced by GMOne-Step 2.0)Genomeditech/GM-040501
Cell Culture

Cell Recovery

Recovery Medium: DMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+125 μg/mL Hygromycin+0.75 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a)          Subculturing is necessary when the cell density reaches 80%. It is recommended to perform subculturing at a ratio of 1:3 to 1:4 every 2-3 days. Ensure that the density does not exceed 80%, as overcrowding can lead to reduced viability due to compression.

b)         Remove and discard culture medium.

c)          Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.

d)         Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).

e)          Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

f)          Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

g)         After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

h)         Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a)          Upon initial thawing, a higher number of dead cells is observed, which is a normal phenomenon. Significant improvement is seen after adaptation. Once the cells reach a stable state, the number of dead cells decreases after subculturing and the cell growth rate becomes stable.

b)         Ensure that the cell density does not exceed 80%, as overcrowding may lead to reduced viability due to compression.



Citations

Qian X, Li H, Teng F, et al. Bi-functional molecules: U.S. Patent Application 18/253,398[P]. 2024-2-8.

Li TT, Su XW, Chen LL, Zhang WN, Zhang JP, Wang Y, Xu WH. Roxarsone inhibits hepatic stellate cell activation and ameliorates liver fibrosis by blocking TGF-β1/Smad signaling pathway. Int Immunopharmacol. 2023 Jan;114:109527. Epub 2022 Dec 19. PMID: 36700762.

Wu ZH, Li N, Gao ZZ, Chen G, Nie L, Zhou YQ, Jiang MZ, Chen Y, Chen J, Mei XF, Hu F, Wang HB. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy. Cancers (Basel). 2022 Oct 10;14(19):4964. PMID: 36230887.

Rui Y, Han X, Jiang A, Hu J, Li M, Liu B, Qian F, Huang L. Eucalyptol prevents bleomycin-induced pulmonary fibrosis and M2 macrophage polarization. Eur J Pharmacol. 2022 Sep 15;931:175184. Epub 2022 Aug 12. PMID: 35964659.

Current Position:Product Center > Cell lines > Cytokines > TGF-β > TGF-β Reporter HEK-293 cell line
classify
TGF-β Reporter HEK-293 cell line
Description
Cat. No: GM-C05346
Product: TGF-β Reporter HEK-293 Cell Line


TGF-Beta (Transforming Growth Factor-Beta) is a type of multifunctional cytokine and a member of the cytokine superfamily. It plays a vital role in various biological processes such as cell growth, differentiation, apoptosis, and immune regulation. The TGF-Beta family includes three homologous isoforms: TGF-β1, TGF-β2, and TGF-β3. While structurally similar, they function differently across various tissues and cell types.

TGF-Beta works by binding to TGF-Beta receptors on cell surfaces, activating downstream signaling pathways. The main pathways include the Smad-dependent and non-Smad pathways. Smad proteins play a critical role in TGF-Beta signal transduction, relocating to the cell nucleus once receptors are activated to regulate the expression of specific genes.

TGF-β Reporter HEK-293 Cell Line is a clonal stable HEK-293 cell line with constitutive expression of the TβRI, endogenously expresses TβRII gene and some adapter membrane molecules, along with signal-dependent expression of a luciferase reporter gene. When TGF-β binds to TGF-β receptors, it activates  downstream signaling pathways, leading to the expression of luciferase. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to this signaling pathway.
Data
Response to Recombinant Human TGF-beta 1. TGF-β Reporter HEK-293 Cell Line (Cat. GM-C05346) at a concentration of 2.5E4 cells/well (96-well format) was stimulated with serial dilutions of Recombinant Human TGF-beta 1 (novoprotein/CA59) in assay buffer (DMEM +10% FBS +1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Assay System (Cat. GM-040501). The maximum induction fold was approximately [8.0]. Data are shown by drug mass concentration.
Specifications
Cat. NoGM-C05346
ProductTGF-β Reporter HEK-293 Cell Line
Product Format1 vial of frozen cells
Quantity5E6 Cells per vial,1 mL
Storage ConditionsLiquid nitrogen immediately upon receipt
Recovery MediumDMEM+10% FBS+1% P.S
Growth mediumDMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+125 μg/mL Hygromycin+0.75 μg/mL Puromycin
NoteNone
Freezing Medium90% FBS+10% DMSO
Growth propertiesAdherent
Growth Conditions37°C, 5% CO₂
Safety considerationsBiosafety Level 2
Mycoplasma TestingThe cell line has been screened to confirm the absence of Mycoplasma species.
Materials
ReagentOrdering Information
DMEM, high glucose, with glutamineBiological Industries/01-052-1ACS
Fetal Bovine SerumCegrogen biotech/A0500-3010
Pen/StrepThermo/15140-122
BlasticidinGenomeditech/GM-040404
G418Genomeditech/GM-040402
HygromycinGenomeditech/GM-040403
PuromycinGenomeditech/GM-040401
Recombinant Human TGF-beta 1Novoprotein/CA59
Luciferase Reporter Gene Aassy Kit(the Kit is replaced by GMOne-Step 2.0)Genomeditech/GM-040501
Cell Culture

Cell Recovery

Recovery Medium: DMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: DMEM+10% FBS+1% P.S+4 μg/mL Blasticidin+400 μg/mL G418+125 μg/mL Hygromycin+0.75 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a)          Subculturing is necessary when the cell density reaches 80%. It is recommended to perform subculturing at a ratio of 1:3 to 1:4 every 2-3 days. Ensure that the density does not exceed 80%, as overcrowding can lead to reduced viability due to compression.

b)         Remove and discard culture medium.

c)          Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.

d)         Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).

e)          Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

f)          Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

g)         After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

h)         Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a)          Upon initial thawing, a higher number of dead cells is observed, which is a normal phenomenon. Significant improvement is seen after adaptation. Once the cells reach a stable state, the number of dead cells decreases after subculturing and the cell growth rate becomes stable.

b)         Ensure that the cell density does not exceed 80%, as overcrowding may lead to reduced viability due to compression.



Citations

Qian X, Li H, Teng F, et al. Bi-functional molecules: U.S. Patent Application 18/253,398[P]. 2024-2-8.

Li TT, Su XW, Chen LL, Zhang WN, Zhang JP, Wang Y, Xu WH. Roxarsone inhibits hepatic stellate cell activation and ameliorates liver fibrosis by blocking TGF-β1/Smad signaling pathway. Int Immunopharmacol. 2023 Jan;114:109527. Epub 2022 Dec 19. PMID: 36700762.

Wu ZH, Li N, Gao ZZ, Chen G, Nie L, Zhou YQ, Jiang MZ, Chen Y, Chen J, Mei XF, Hu F, Wang HB. Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF-β for Anticancer Immunotherapy. Cancers (Basel). 2022 Oct 10;14(19):4964. PMID: 36230887.

Rui Y, Han X, Jiang A, Hu J, Li M, Liu B, Qian F, Huang L. Eucalyptol prevents bleomycin-induced pulmonary fibrosis and M2 macrophage polarization. Eur J Pharmacol. 2022 Sep 15;931:175184. Epub 2022 Aug 12. PMID: 35964659.

Tel: 400-627-9288
Message consultation
reset
submit
Service
WhatApp
Phone
Message
Message consultation
reset
submit